{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T09:03:59Z","timestamp":1794128639175,"version":"4.8.0"},"reference-count":485,"publisher":"Oxford University Press (OUP)","issue":"39","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,10,14]]},"DOI":"10.1093\/eurheartj\/ehw272","type":"journal-article","created":{"date-parts":[[2016,8,27]],"date-time":"2016-08-27T20:39:10Z","timestamp":1472330350000},"page":"2999-3058","source":"Crossref","is-referenced-by-count":2411,"title":["2016 ESC\/EAS Guidelines for the Management of Dyslipidaemias"],"prefix":"10.1093","volume":"37","author":[{"given":"Alberico L","family":"Catapano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"De Backer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olov","family":"Wiklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M John","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Drexel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arno W","family":"Hoes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona S","family":"Jennings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Landmesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terje R","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u017deljko","family":"Reiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Riccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marja-Riita","family":"Taskinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lale","family":"Tokgozoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W M Monique","family":"Verschuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalambos","family":"Vlachopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Zamorano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Therese","family":"Cooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ESC Scientific Document Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Badimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Funck-Brentano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Agewall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Bar\u00f3n-Esquivias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Bor\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Bruckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Cordero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Corsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantaleo","family":"Giannuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Gueyffier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goran","family":"Krsta\u010di\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Lettino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Lionis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y H","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Marques-Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davor","family":"Milicic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Pedro-Botet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo F","family":"Piepoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelos G","family":"Rigopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Ruschitzka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Tu\u00f1\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"von Eckardstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Vrablik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reuven","family":"Zimlichman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Zamorano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Aboyans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Achenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Agewall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Badimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Bar\u00f3n-Esquivias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Baumgartner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen J","family":"Bax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9ctor","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scipione","family":"Carerj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c7etin","family":"Erol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Fitzsimons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Gaemperli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulus","family":"Kirchhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Kolh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizio","family":"Lancellotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y H","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Nihoyannopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo F","family":"Piepoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Roffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Torbicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ant\u00f3nio","family":"Vaz Carneiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parounak H","family":"Zelveian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Siostrzonek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firdovsi","family":"Ibrahimov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volha","family":"Sujayeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc J","family":"Claeys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belma","family":"Pojski\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Postadzhiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davor","family":"Mili\u010di\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George C","family":"Georgiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Rosolova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Klausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margus","family":"Viigimaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Kervinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasko","family":"Kedev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Ferri\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalva","family":"Petriashvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Kintscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loukianos","family":"Rallidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00f3bert","family":"G\u00e1bor Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorarinn","family":"Gu\u00f0nason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaakov","family":"Henkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Francesco","family":"Mureddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisulu","family":"Mussagaliyeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranvera","family":"Ibrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkin","family":"Mirrakhimov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavs","family":"Latkovskis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisham","family":"Ben Lamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimvydas","family":"Slapikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Dingli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Ivanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janneke","family":"Wittekoek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Hovland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Rynkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quiteria","family":"Rato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marat","family":"Ezhov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Zavatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan A","family":"Nedeljkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Pella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zlatko","family":"Fras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domingo","family":"Marzal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Mach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faouzi","family":"Addad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meral","family":"Kay\u0131kc\u0131oglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olena","family":"Mitchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,8,28]]},"reference":[{"key":"2026080920454422700_ehw272C1","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1093\/eurheartj\/ehv428","article-title":"Cardiovascular disease in Europe\u2014epidemiological update 2015","volume":"36","author":"Townsend","year":"2015","journal-title":"Eur Heart J"},{"key":"2026080920454422700_ehw272C2","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/HJR.0b013e32832b38a1","article-title":"Re-evaluating the Rose approach: comparative benefits of the population and high-risk preventive strategies","volume":"16","author":"Cooney","year":"2009","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"2026080920454422700_ehw272C3","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1161\/CIRCULATIONAHA.111.060681","article-title":"Healthy lifestyle through young adulthood and the presence of low cardiovascular disease risk profile in middle age: the Coronary Artery Risk Development in (Young) Adults (CARDIA) study","volume":"125","author":"Liu","year":"2012","journal-title":"Circulation"},{"key":"2026080920454422700_ehw272C4","article-title":"Comparative quantification of health risks: global and regional burden of disease attributable to selected major risk factors","author":"Ezzati","year":"2004"},{"key":"2026080920454422700_ehw272C5","article-title":"Global status report on noncommunicable diseases 2010","author":"World Health Organization","year":"2011"},{"key":"2026080920454422700_ehw272C6","first-page":"1635","article-title":"European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)","volume":"33","author":"Perk","year":"2012","journal-title":"Eur Heart J"},{"key":"2026080920454422700_ehw272C7","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001029","article-title":"Cost-effectiveness of a European preventive cardiology programme in primary care: a Markov modelling approach","volume":"2","author":"Mistry","year":"2012  11","journal-title":"BMJ Open"},{"key":"2026080920454422700_ehw272C8","volume-title":"European Cardiovascular Disease Statistics, 2012","author":"Nichols","year":"2012"},{"key":"2026080920454422700_ehw272C9","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1161\/CIR.0b013e31820a55f5","article-title":"Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association","volume":"123","author":"Heidenreich","year":"2011","journal-title":"Circulation"},{"key":"2026080920454422700_ehw272C10","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/eurheartj\/eht232","article-title":"Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study","volume":"35","author":"McConnachie","year":"2014","journal-title":"Eur Heart J"},{"key":"2026080920454422700_ehw272C11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11140","article-title":"A systematic review and economic evaluation of statins for the prevention of coronary events","volume":"11","author":"Ward","year":"2007","journal-title":"Health Technol Assess"},{"key":"2026080920454422700_ehw272C12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2165\/11539150-000000000-00000","article-title":"The cost effectiveness of statin therapies in Spain in 2010, after the introduction of generics and reference prices","volume":"10","author":"Plans-Rubio","year":"2010","journal-title":"Am J Cardiovasc Drugs"},{"key":"2026080920454422700_ehw272C13","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/eurheartj\/ehn554","article-title":"Modelling the decreasing coronary heart disease mortality in Sweden between 1986 and 2002","volume":"30","author":"Bjorck","year":"2009","journal-title":"Eur Heart J"},{"key":"2026080920454422700_ehw272C14","doi-asserted-by":"crossref","first-page":"e13957","DOI":"10.1371\/journal.pone.0013957","article-title":"Analysing the large decline in coronary heart disease mortality in the Icelandic population aged 25\u201374 between the years 1981 and 2006","volume":"5","author":"Aspelund","year":"2010","journal-title":"PLoS One"},{"key":"2026080920454422700_ehw272C15","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCOUTCOMES.113.000264","article-title":"Explaining the decline in coronary heart disease mortality in Portugal between 1995 and 2008","volume":"6","author":"Pereira","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026080920454422700_ehw272C16","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1186\/1471-2458-13-1135","article-title":"Explaining the decline in coronary heart disease mortality in Turkey between 1995 and 2008","volume":"13","author":"Unal","year":"2013","journal-title":"BMC Public Health"},{"key":"2026080920454422700_ehw272C17","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa1406656","article-title":"Demographic and epidemiologic drivers of global cardiovascular mortality","volume":"372","author":"Roth","year":"2015","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C18","doi-asserted-by":"crossref","first-page":"e41842","DOI":"10.1371\/journal.pone.0041842","article-title":"Which interventions offer best value for money in primary prevention of cardiovascular disease","volume":"7","author":"Cobiac","year":"2012","journal-title":"PLoS One"},{"key":"2026080920454422700_ehw272C19","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jval.2014.03.1722","article-title":"An economic evaluation of salt reduction policies to reduce coronary heart disease in England: a policy modeling study","volume":"17","author":"Collins","year":"2014","journal-title":"Value Health"},{"key":"2026080920454422700_ehw272C20","doi-asserted-by":"crossref","first-page":"e84445","DOI":"10.1371\/journal.pone.0084445","article-title":"A cost effectiveness analysis of salt reduction policies to reduce coronary heart disease in four Eastern Mediterranean countries","volume":"9","author":"Mason","year":"2014","journal-title":"PLoS One"},{"key":"2026080920454422700_ehw272C21","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-002837","article-title":"Modelling the impact of specific food policy options on coronary heart disease and stroke deaths in Ireland","volume":"3","author":"O'Keeffe","year":"2013","journal-title":"BMJ Open"},{"key":"2026080920454422700_ehw272C22","doi-asserted-by":"crossref","first-page":"e0118353","DOI":"10.1371\/journal.pone.0118353","article-title":"Comparing different policy scenarios to reduce the consumption of ultra-processed foods in UK: impact on cardiovascular disease mortality using a modelling approach","volume":"10","author":"Moreira","year":"2015","journal-title":"PLoS One"},{"key":"2026080920454422700_ehw272C23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2143\/AC.64.1.2034354","article-title":"Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium","volume":"64","author":"Neyt","year":"2009","journal-title":"Acta Cardiol"},{"key":"2026080920454422700_ehw272C24","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1185\/03007990802144705","article-title":"Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men","volume":"24","author":"Peura","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"2026080920454422700_ehw272C25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/11586760-000000000-00000","article-title":"Statins for cardiovascular prevention according to different strategies: a cost analysis","volume":"11","author":"Ito","year":"2011","journal-title":"Am J Cardiovasc Drugs"},{"key":"2026080920454422700_ehw272C26","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.clinthera.2014.01.008","article-title":"Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension: a scenario analysis for the Netherlands","volume":"36","author":"Stevanovic","year":"2014","journal-title":"Clin Ther"},{"key":"2026080920454422700_ehw272C27","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2261-12-26","article-title":"Choice of generic antihypertensive drugs for the primary prevention of cardiovascular disease\u2014a cost-effectiveness analysis","volume":"12","author":"Wisloff","year":"2012","journal-title":"BMC Cardiovasc Disord"},{"key":"2026080920454422700_ehw272C28","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1093\/eurheartj\/ehr080","article-title":"Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study","volume":"32","author":"Banegas","year":"2011","journal-title":"Eur Heart J"},{"key":"2026080920454422700_ehw272C29","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/HJR.0b013e3283383f30","article-title":"EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries","volume":"17","author":"Kotseva","year":"2010","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"2026080920454422700_ehw272C30","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1524-4733.2008.00447.x","article-title":"The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients","volume":"12","author":"Cherry","year":"2009","journal-title":"Value Health"},{"key":"2026080920454422700_ehw272C31","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.atherosclerosis.2011.04.014","article-title":"Cost-effectiveness of enhancing adherence to therapy with statins in the setting of primary cardiovascular prevention. Evidence from an empirical approach based on administrative databases","volume":"217","author":"Corrao","year":"2011","journal-title":"Atherosclerosis"},{"key":"2026080920454422700_ehw272C32","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/MLR.0b013e3181d567bd","article-title":"Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs","volume":"48","author":"Dragomir","year":"2010","journal-title":"Med Care"},{"key":"2026080920454422700_ehw272C33","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1136\/bmj.326.7404.1419","article-title":"A strategy to reduce cardiovascular disease by more than 80%","volume":"326","author":"Wald","year":"2003","journal-title":"BMJ"},{"key":"2026080920454422700_ehw272C34","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(06)69252-0","article-title":"Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis","volume":"368","author":"Gaziano","year":"2006","journal-title":"Lancet"},{"key":"2026080920454422700_ehw272C35","doi-asserted-by":"crossref","first-page":"e000363","DOI":"10.1136\/bmjopen-2011-000363","article-title":"The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population","volume":"1","author":"van Gils","year":"2011","journal-title":"BMJ Open"},{"key":"2026080920454422700_ehw272C36","doi-asserted-by":"crossref","first-page":"590","DOI":"10.2105\/AJPH.2009.185652","article-title":"A framework for public health action: the health impact pyramid","volume":"100","author":"Frieden","year":"2010","journal-title":"Am J Public Health"},{"key":"2026080920454422700_ehw272C37","doi-asserted-by":"crossref","first-page":"304","DOI":"10.4065\/mcp.2010.0575","article-title":"Medication adherence: WHO cares?","volume":"86","author":"Brown","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"2026080920454422700_ehw272C38","author":"National Institute for Health and Care Excellence"},{"key":"2026080920454422700_ehw272C39","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2471\/BLT.08.057885","article-title":"Cardiovascular risk factor trends and potential for reducing coronary heart disease mortality in the United States of America","volume":"88","author":"Capewell","year":"2010","journal-title":"Bull World Health Org"},{"key":"2026080920454422700_ehw272C40","doi-asserted-by":"crossref","first-page":"d5747","DOI":"10.1136\/bmj.d5747","article-title":"United Nations' dietary policies to prevent cardiovascular disease","volume":"343","author":"Mozaffarian","year":"2011","journal-title":"BMJ"},{"key":"2026080920454422700_ehw272C41","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Framingham Heart Study","volume":"117","author":"D'Agostino","year":"2008","journal-title":"Circulation"},{"key":"2026080920454422700_ehw272C42","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0195-668X(03)00114-3","article-title":"Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project","volume":"24","author":"Conroy","year":"2003","journal-title":"Eur Heart J"},{"key":"2026080920454422700_ehw272C43","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/hrt.2006.108167","article-title":"Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC)","volume":"93","author":"Woodward","year":"2007","journal-title":"Heart"},{"key":"2026080920454422700_ehw272C44","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/bmj.39609.449676.25","article-title":"Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2","volume":"336","author":"Hippisley-Cox","year":"2008","journal-title":"BMJ"},{"key":"2026080920454422700_ehw272C45","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/hc0302.102575","article-title":"Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study","volume":"105","author":"Assmann","year":"2002","journal-title":"Circulation"},{"key":"2026080920454422700_ehw272C46","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1161\/CIRCULATIONAHA.108.814251","article-title":"C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men","volume":"118","author":"Ridker","year":"2008","journal-title":"Circulation"},{"key":"2026080920454422700_ehw272C47","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/jama.297.6.611","article-title":"Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score","volume":"297","author":"Ridker","year":"2007","journal-title":"JAMA"},{"key":"2026080920454422700_ehw272C48","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/ije\/dyh405","article-title":"Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort Study prediction equation","volume":"34","author":"Ferrario","year":"2005","journal-title":"Int J Epidemiol"},{"issue":"(25 Suppl 2)","key":"2026080920454422700_ehw272C49","first-page":"S49","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation"},{"key":"2026080920454422700_ehw272C50","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S2213-8587(15)00081-9","article-title":"A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys","volume":"3","author":"Hajifathalian","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026080920454422700_ehw272C51","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jacc.2009.07.020","article-title":"Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians","volume":"54","author":"Cooney","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026080920454422700_ehw272C52","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1161\/CIRCULATIONAHA.109.852756","article-title":"Cardiovascular risk-estimation systems in primary prevention: do they differ? Do they make a difference? Can we see the future?","volume":"122","author":"Cooney","year":"2010","journal-title":"Circulation"},{"key":"2026080920454422700_ehw272C53","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1161\/CIRCULATIONAHA.105.548206","article-title":"Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age","volume":"113","author":"Lloyd-Jones","year":"2006","journal-title":"Circulation"},{"key":"2026080920454422700_ehw272C54","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1177\/2047487315588390","article-title":"Cardiovascular risk estimation in older persons: SCORE O.P","volume":"23","author":"Cooney","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"2026080920454422700_ehw272C55","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.atherosclerosis.2009.02.041","article-title":"HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk","volume":"206","author":"Cooney","year":"2009","journal-title":"Atherosclerosis"},{"key":"2026080920454422700_ehw272C56","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/HJR.0b013e3283213140","article-title":"How much does HDL cholesterol add to risk estimation? A report from the SCORE Investigators","volume":"16","author":"Cooney","year":"2009","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"2026080920454422700_ehw272C57","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1093\/eurheartj\/ehv251","article-title":"The high-density lipoprotein-adjusted SCORE model worsens SCORE-based risk classification in a contemporary population of 30,824 Europeans: the Copenhagen General Population Study","volume":"36","author":"Mortensen","year":"2015","journal-title":"Eur Heart J"},{"key":"2026080920454422700_ehw272C58","doi-asserted-by":"crossref","first-page":"438","DOI":"10.7326\/0003-4819-156-6-201203200-00006","article-title":"Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study","volume":"156","author":"Kavousi","year":"2012","journal-title":"Ann Intern Med"},{"key":"2026080920454422700_ehw272C59","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2012.9624","article-title":"Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals","volume":"308","author":"Yeboah","year":"2012","journal-title":"JAMA"},{"key":"2026080920454422700_ehw272C60","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.atherosclerosis.2015.05.007","article-title":"The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society","volume":"241","author":"Vlachopoulos","year":"2015","journal-title":"Atherosclerosis"},{"key":"2026080920454422700_ehw272C61","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026080920454422700_ehw272C62","doi-asserted-by":"crossref","first-page":"b2376","DOI":"10.1136\/bmj.b2376","article-title":"The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials","volume":"338","author":"Brugts","year":"2009","journal-title":"BMJ"},{"key":"2026080920454422700_ehw272C63","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C64","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists' (CTT) Collaboration","year":"2010","journal-title":"Lancet"},{"key":"2026080920454422700_ehw272C65","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Cholesterol Treatment Trialists' (CTT) Collaboration","year":"2015","journal-title":"Lancet"},{"key":"2026080920454422700_ehw272C66","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Cholesterol Treatment Trialists' (CTT) Collaborators","year":"2012","journal-title":"Lancet"},{"key":"2026080920454422700_ehw272C67","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","article-title":"The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management","volume":"2","author":"Hegele","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026080920454422700_ehw272C68","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.jacc.2008.08.039","article-title":"Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients","volume":"52","author":"Mills","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026080920454422700_ehw272C69","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"2026080920454422700_ehw272C70","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"SPRINT Research Group","year":"2015","journal-title":"N Engl J Med"},{"issue":"(25 Suppl 2)","key":"2026080920454422700_ehw272C71","first-page":"S1","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"2026080920454422700_ehw272C72","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.atherosclerosis.2013.12.016","article-title":"Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM Collaborative Project Group","volume":"233","author":"Langlois","year":"2014","journal-title":"Atherosclerosis"},{"key":"2026080920454422700_ehw272C73","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2174\/157016111795495549","article-title":"Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement","volume":"9","author":"Kolovou","year":"2011","journal-title":"Curr Vasc Pharmacol"},{"key":"2026080920454422700_ehw272C74","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/157016111795495530","article-title":"Diagnostic value of postprandial triglyceride testing in healthy subjects: a meta-analysis","volume":"9","author":"Mihas","year":"2011","journal-title":"Curr Vasc Pharmacol"},{"key":"2026080920454422700_ehw272C75","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"key":"2026080920454422700_ehw272C76","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehs431","article-title":"Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction","volume":"34","author":"Jorgensen","year":"2013","journal-title":"Eur Heart J"},{"key":"2026080920454422700_ehw272C77","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1373\/clinchem.2010.157164","article-title":"Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58 434 individuals from the Copenhagen General Population Study","volume":"57","author":"Langsted","year":"2011","journal-title":"Clin Chem"},{"key":"2026080920454422700_ehw272C78","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1136\/heartjnl-2014-305623","article-title":"Seasonality of cardiovascular risk factors: an analysis including over 230 000 participants in 15 countries","volume":"100","author":"Marti-Soler","year":"2014","journal-title":"Heart"},{"key":"2026080920454422700_ehw272C79","doi-asserted-by":"crossref","first-page":"g4356","DOI":"10.1136\/bmj.g4356","article-title":"Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance","volume":"349","author":"Rabar","year":"2014","journal-title":"BMJ"},{"issue":"(Suppl 2)","key":"2026080920454422700_ehw272C80","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/heartjnl-2014-305693","article-title":"Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3)","volume":"100","author":"JBS3","year":"2014","journal-title":"Heart"},{"key":"2026080920454422700_ehw272C81","doi-asserted-by":"crossref","first-page":"261878","DOI":"10.1155\/2014\/261878","article-title":"Validation of the Friedewald formula in patients with metabolic syndrome","volume":"2014","author":"Knopfholz","year":"2014","journal-title":"Cholesterol"},{"key":"2026080920454422700_ehw272C82","article-title":"Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease","author":"National Institute for Health and Care Excellence","year":"2014"},{"key":"2026080920454422700_ehw272C83","first-page":"2499","article-title":"Thompson SG, Boekholdt SM, Sattar N, Packard C, Gudnason V, Danesh J. Lipid-related markers and cardiovascular disease prediction","volume":"307","author":"Emerging Risk Factors Collaboration","year":"2012","journal-title":"JAMA"},{"key":"2026080920454422700_ehw272C84","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jama.2012.366","article-title":"Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis","volume":"307","author":"Boekholdt","year":"2012","journal-title":"JAMA"},{"key":"2026080920454422700_ehw272C85","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.amjcard.2012.07.007","article-title":"Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials","volume":"110","author":"Robinson","year":"2012","journal-title":"Am J Cardiol"},{"key":"2026080920454422700_ehw272C86","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026080920454422700_ehw272C87","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0140-6736(10)60545-4","article-title":"Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies","volume":"375","author":"Triglyceride Coronary Disease Genetics, Consortium and Emerging Risk Factors Collaboration","year":"2010","journal-title":"Lancet"},{"key":"2026080920454422700_ehw272C88","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ng.2795","article-title":"Common variants associated with plasma triglycerides and risk for coronary artery disease","volume":"45","author":"Do","year":"2013","journal-title":"Nat Genet"},{"key":"2026080920454422700_ehw272C89","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/eurheartj\/eht571","article-title":"Mendelian randomization of blood lipids for coronary heart disease","volume":"36","author":"Holmes","year":"2015","journal-title":"Eur Heart J"},{"key":"2026080920454422700_ehw272C90","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Emerging Risk Factors Collaboration","year":"2009","journal-title":"JAMA"},{"key":"2026080920454422700_ehw272C91","doi-asserted-by":"crossref","first-page":"E500","DOI":"10.1210\/jc.2010-0450","article-title":"Genetically elevated apolipoprotein A-I, high-density lipoprotein cholesterol levels, and risk of ischemic heart disease","volume":"95","author":"Haase","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2026080920454422700_ehw272C92","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"},{"key":"2026080920454422700_ehw272C93","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa1001689","article-title":"Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis","volume":"364","author":"Khera","year":"2011","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C94","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1161\/ATVBAHA.113.301373","article-title":"Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks","volume":"33","author":"Li","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026080920454422700_ehw272C95","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","article-title":"HDL cholesterol efflux capacity and incident cardiovascular events","volume":"371","author":"Rohatgi","year":"2014","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C96","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.106.637793","article-title":"Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies","volume":"115","author":"Sarwar","year":"2007","journal-title":"Circulation"},{"key":"2026080920454422700_ehw272C97","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00043798-199604000-00014","article-title":"Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies","volume":"3","author":"Hokanson","year":"1996","journal-title":"J Cardiovasc Risk"},{"key":"2026080920454422700_ehw272C98","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.298.3.309","article-title":"Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women","volume":"298","author":"Bansal","year":"2007","journal-title":"JAMA"},{"key":"2026080920454422700_ehw272C99","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA"},{"key":"2026080920454422700_ehw272C100","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1373\/clinchem.2008.111401","article-title":"Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"55","author":"Charlton-Menys","year":"2009","journal-title":"Clin Chem"},{"key":"2026080920454422700_ehw272C101","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1001\/jama.298.7.776","article-title":"Clinical utility of different lipid measures for prediction of coronary heart disease in men and women","volume":"298","author":"Ingelsson","year":"2007","journal-title":"JAMA"},{"key":"2026080920454422700_ehw272C102","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1007\/s00125-010-1806-9","article-title":"Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes","volume":"53","author":"Taskinen","year":"2010","journal-title":"Diabetologia"},{"key":"2026080920454422700_ehw272C103","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCOUTCOMES.110.959247","article-title":"A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk","volume":"4","author":"Sniderman","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026080920454422700_ehw272C104","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0021-9150(03)00025-X","article-title":"Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders","volume":"168","author":"Onat","year":"2003","journal-title":"Atherosclerosis"},{"key":"2026080920454422700_ehw272C105","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1161\/01.CIR.102.16.1886","article-title":"VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial","volume":"102","author":"Sacks","year":"2000","journal-title":"Circulation"},{"key":"2026080920454422700_ehw272C106","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute","year":"2014","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C107","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"Jorgensen","year":"2014","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C108","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1161\/CIRCRESAHA.111.300367","article-title":"Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans","volume":"112","author":"Graham","year":"2013","journal-title":"Circ Res"},{"key":"2026080920454422700_ehw272C109","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"2026080920454422700_ehw272C110","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026080920454422700_ehw272C111","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a): resurrected by genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J Intern Med"},{"key":"2026080920454422700_ehw272C112","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1373\/clinchem.2003.023689","article-title":"Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions","volume":"49","author":"Marcovina","year":"2003","journal-title":"Clin Chem"},{"key":"2026080920454422700_ehw272C113","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jacc.2014.03.061","article-title":"Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study","volume":"64","author":"Willeit","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026080920454422700_ehw272C114","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jacc.2012.12.023","article-title":"Extreme lipoprotein(a) levels and improved cardiovascular risk prediction","volume":"61","author":"Kamstrup","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026080920454422700_ehw272C115","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C116","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"727","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C117","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0021-9150(93)90102-Z","article-title":"The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover","volume":"101","author":"Seed","year":"1993","journal-title":"Atherosclerosis"},{"key":"2026080920454422700_ehw272C118","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/01.mol.0000236367.42755.c1","article-title":"Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease","volume":"17","author":"Packard","year":"2006","journal-title":"Curr Opin Lipidol"},{"key":"2026080920454422700_ehw272C119","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.atherosclerosis.2006.05.007","article-title":"LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"192","author":"Mora","year":"2007","journal-title":"Atherosclerosis"},{"key":"2026080920454422700_ehw272C120","first-page":"15","article-title":"Genetic insights into cardiometabolic risk factors","volume":"35","author":"Whitfield","year":"2014","journal-title":"Clin Biochem Rev"},{"key":"2026080920454422700_ehw272C121","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"2026080920454422700_ehw272C122","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1373\/clinchem.2014.231365","article-title":"Refinement of variant selection for the LDL cholesterol genetic risk score in the diagnosis of the polygenic form of clinical familial hypercholesterolemia and replication in samples from 6 countries","volume":"61","author":"Futema","year":"2015","journal-title":"Clin Chem"},{"key":"2026080920454422700_ehw272C123","first-page":"2975","article-title":"Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment","volume":"36","author":"Soran","year":"2015","journal-title":"Eur Heart J"},{"key":"2026080920454422700_ehw272C124","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1080\/07853890801964955","article-title":"Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL)","volume":"40","author":"Holme","year":"2008","journal-title":"Ann Med"},{"key":"2026080920454422700_ehw272C125","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"European Association for Cardiovascular Prevention & Rehabilitation","year":"2011","journal-title":"Eur Heart J"},{"key":"2026080920454422700_ehw272C126","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jacc.2010.09.082","article-title":"Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg\/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)","volume":"57","author":"Hsia","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026080920454422700_ehw272C127","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group","volume":"317","year":"1998","journal-title":"BMJ"},{"key":"2026080920454422700_ehw272C128","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C129","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1001\/jama.282.24.2340","article-title":"Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials","volume":"282","author":"LaRosa","year":"1999","journal-title":"JAMA"},{"key":"2026080920454422700_ehw272C130","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2796.2006.01644.x","article-title":"Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B\/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies","volume":"259","author":"Thompson","year":"2006","journal-title":"J Intern Med"},{"key":"2026080920454422700_ehw272C131","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jacc.2008.10.024","article-title":"Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk","volume":"53","author":"Robinson","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026080920454422700_ehw272C132","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.amjmed.2013.12.014","article-title":"Diets to prevent coronary heart disease 1957\u20132013: what have we learned","volume":"127","author":"Dalen","year":"2014","journal-title":"Am J Med"},{"key":"2026080920454422700_ehw272C133","doi-asserted-by":"crossref","DOI":"10.1161\/01.cir.0000437740.48606.d1","article-title":"2013 AHA\/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","author":"Eckel","year":"2014","journal-title":"Circulation"},{"key":"2026080920454422700_ehw272C134","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/archinternmed.2009.38","article-title":"A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease","volume":"169","author":"Mente","year":"2009","journal-title":"Arch Intern Med"},{"key":"2026080920454422700_ehw272C135","doi-asserted-by":"crossref","first-page":"398","DOI":"10.7326\/M13-1788","article-title":"Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis","volume":"160","author":"Chowdhury","year":"2014","journal-title":"Ann Intern Med"},{"key":"2026080920454422700_ehw272C136","doi-asserted-by":"crossref","first-page":"e1000252","DOI":"10.1371\/journal.pmed.1000252","article-title":"Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials","volume":"7","author":"Mozaffarian","year":"2010","journal-title":"PLoS Med"},{"key":"2026080920454422700_ehw272C137","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa1200303","article-title":"Primary prevention of cardiovascular disease with a Mediterranean diet","volume":"368","author":"Estruch","year":"2013","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C138","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1161\/01.CIR.99.6.779","article-title":"Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study","volume":"99","author":"de Lorgeril","year":"1999","journal-title":"Circulation"},{"issue":"(Suppl 2)","key":"2026080920454422700_ehw272C139","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1038\/sj.ejcn.1602973","article-title":"Health effects of trans-fatty acids: experimental and observational evidence","volume":"63","author":"Mozaffarian","year":"2009","journal-title":"Eur J Clin Nutr"},{"key":"2026080920454422700_ehw272C140","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/ajcn\/69.1.30","article-title":"Cholesterol-lowering effects of dietary fiber: a meta-analysis","volume":"69","author":"Brown","year":"1999","journal-title":"Am J Clin Nutr"},{"key":"2026080920454422700_ehw272C141","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3945\/ajcn.115.109165","article-title":"Whole-grain and blood lipid changes in apparently healthy adults: a systematic review and meta-analysis of randomized controlled studies","volume":"102","author":"Hollaender","year":"2015","journal-title":"Am J Clin Nutr"},{"key":"2026080920454422700_ehw272C142","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.atherosclerosis.2013.11.043","article-title":"Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease","volume":"232","author":"Gylling","year":"2014","journal-title":"Atherosclerosis"},{"key":"2026080920454422700_ehw272C143","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.plefa.2011.02.001","article-title":"A comparison of the LDL-cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: results of a meta-analysis of randomized, placebo-controlled trials","volume":"85","author":"Musa-Veloso","year":"2011","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"2026080920454422700_ehw272C144","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.amjcard.2008.02.056","article-title":"Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction","volume":"101","author":"Lu","year":"2008","journal-title":"Am J Cardiol"},{"key":"2026080920454422700_ehw272C145","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1001\/archinternmed.2010.382","article-title":"Marked variability of monacolin levels in commercial red yeast rice products: buyer beware","volume":"170","author":"Gordon","year":"2010","journal-title":"Arch Intern Med"},{"key":"2026080920454422700_ehw272C146","doi-asserted-by":"crossref","first-page":"e98611","DOI":"10.1371\/journal.pone.0098611","article-title":"A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"key":"2026080920454422700_ehw272C147","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/ajcn\/56.2.320","article-title":"Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis","volume":"56","author":"Dattilo","year":"1992","journal-title":"Am J Clin Nutr"},{"key":"2026080920454422700_ehw272C148","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/archinte.166.3.285","article-title":"Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials","volume":"166","author":"Nordmann","year":"2006","journal-title":"Arch Intern Med"},{"key":"2026080920454422700_ehw272C149","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/ajcn\/40.2.351","article-title":"Serum cholesterol response to dietary cholesterol","volume":"40","author":"Keys","year":"1984","journal-title":"Am J Clin Nutr"},{"key":"2026080920454422700_ehw272C150","first-page":"CD003817","article-title":"Exercise for overweight or obesity","volume":"4","author":"Shaw","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"2026080920454422700_ehw272C151","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1210\/jc.2004-2350","article-title":"Clinical review: a critical evaluation of the role of soy protein and isoflavone supplementation in the control of plasma cholesterol concentrations","volume":"91","author":"Dewell","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2026080920454422700_ehw272C152","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1136\/bmj.319.7224.1523","article-title":"Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors","volume":"319","author":"Rimm","year":"1999","journal-title":"BMJ"},{"key":"2026080920454422700_ehw272C153","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/1475-2891-12-147","article-title":"A daily glass of red wine associated with lifestyle changes independently improves blood lipids in patients with carotid arteriosclerosis: results from a randomized controlled trial","volume":"12","author":"Droste","year":"2013","journal-title":"Nutr J"},{"key":"2026080920454422700_ehw272C154","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/ajcn\/69.4.632","article-title":"Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis","volume":"69","author":"Yu-Poth","year":"1999","journal-title":"Am J Clin Nutr"},{"key":"2026080920454422700_ehw272C155","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/j.1467-789X.2012.01021.x","article-title":"Systematic review and meta-analysis of clinical trials of the effects of low carbohydrate diets on cardiovascular risk factors","volume":"13","author":"Santos","year":"2012","journal-title":"Obes Rev"},{"key":"2026080920454422700_ehw272C156","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0021-9150(02)00424-0","article-title":"Effects of dietary saturated, monounsaturated and n-3 fatty acids on fasting lipoproteins, LDL size and post-prandial lipid metabolism in healthy subjects","volume":"167","author":"Rivellese","year":"2003","journal-title":"Atherosclerosis"},{"issue":"(5 Suppl)","key":"2026080920454422700_ehw272C157","doi-asserted-by":"crossref","first-page":"1645S","DOI":"10.1093\/ajcn\/65.5.1645S","article-title":"n-3 fatty acids and serum lipoproteins: human studies","volume":"65","author":"Harris","year":"1997","journal-title":"Am J Clin Nutr"},{"key":"2026080920454422700_ehw272C158","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1172\/JCI37385","article-title":"Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight\/obese humans","volume":"119","author":"Stanhope","year":"2009","journal-title":"J Clin Invest"},{"key":"2026080920454422700_ehw272C159","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.nut.2013.08.014","article-title":"Association of fructose consumption and components of metabolic syndrome in human studies: a systematic review and meta-analysis","volume":"30","author":"Kelishadi","year":"2014","journal-title":"Nutrition"},{"key":"2026080920454422700_ehw272C160","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1017\/S0007114514002578","article-title":"Is there a linear relationship between the dose of ruminant trans-fatty acids and cardiovascular risk markers in healthy subjects: results from a systematic review and meta-regression of randomised clinical trials","volume":"112","author":"Gayet-Boyer","year":"2014","journal-title":"Br J Nutr"},{"key":"2026080920454422700_ehw272C161","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ypmed.2009.09.018","article-title":"Impact of progressive resistance training on lipids and lipoproteins in adults: another look at a meta-analysis using prediction intervals","volume":"49","author":"Kelley","year":"2009","journal-title":"Prev Med"},{"key":"2026080920454422700_ehw272C162","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.jacc.2010.09.073","article-title":"The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals","volume":"57","author":"Kastorini","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026080920454422700_ehw272C163","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0091-7435(03)00110-5","article-title":"The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis","volume":"37","author":"Maeda","year":"2003","journal-title":"Prev Med"},{"key":"2026080920454422700_ehw272C164","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.numecd.2007.10.004","article-title":"Non-pharmacological control of plasma cholesterol levels","volume":"18","author":"Poli","year":"2008","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2026080920454422700_ehw272C165","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/ajcn\/77.5.1146","article-title":"Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials","volume":"77","author":"Mensink","year":"2003","journal-title":"Am J Clin Nutr"},{"key":"2026080920454422700_ehw272C166","doi-asserted-by":"crossref","first-page":"g2272","DOI":"10.1136\/bmj.g2272","article-title":"Global, regional, and national consumption levels of dietary fats and oils in 1990 and 2010: a systematic analysis including 266 country-specific nutrition surveys","volume":"348","author":"Micha","year":"2014","journal-title":"BMJ"},{"key":"2026080920454422700_ehw272C167","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s13668-013-0064-0","article-title":"Dietary cholesterol and plasma lipoprotein profiles: randomized-controlled trials","volume":"2","author":"Griffin","year":"2013","journal-title":"Curr Nutr Rep"},{"key":"2026080920454422700_ehw272C168","doi-asserted-by":"crossref","first-page":"1509S","DOI":"10.3945\/ajcn.2009.27113E","article-title":"Genetic influences on blood lipids and cardiovascular disease risk: tools for primary prevention","volume":"89","author":"Ordovas","year":"2009","journal-title":"Am J Clin Nutr"},{"key":"2026080920454422700_ehw272C169","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ahj.2012.04.014","article-title":"Exercise effects on lipids in persons with varying dietary patterns-does diet matter if they exercise? Responses in Studies of a Targeted Risk Reduction Intervention through Defined Exercise I","volume":"164","author":"Huffman","year":"2012","journal-title":"Am Heart J"},{"key":"2026080920454422700_ehw272C170","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s001250051620","article-title":"Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: the KANWU Study","volume":"44","author":"Vessby","year":"2001","journal-title":"Diabetologia"},{"key":"2026080920454422700_ehw272C171","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.clnu.2007.07.005","article-title":"Effects of monounsaturated vs. saturated fat on postprandial lipemia and adipose tissue lipases in type 2 diabetes","volume":"27","author":"Rivellese","year":"2008","journal-title":"Clin Nutr"},{"key":"2026080920454422700_ehw272C172","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jacl.2011.10.018","article-title":"Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review","volume":"6","author":"Jacobson","year":"2012","journal-title":"J Clin Lipidol"},{"key":"2026080920454422700_ehw272C173","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/ajcn\/73.3.560","article-title":"Dietary glycemic load assessed by food-frequency questionnaire in relation to plasma high-density-lipoprotein cholesterol and fasting plasma triacylglycerols in postmenopausal women","volume":"73","author":"Liu","year":"2001","journal-title":"Am J Clin Nutr"},{"key":"2026080920454422700_ehw272C174","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.2337\/dc09-0266","article-title":"Effects of a plant-based high-carbohydrate\/high-fiber diet versus high-monounsaturated fat\/low-carbohydrate diet on postprandial lipids in type 2 diabetic patients","volume":"32","author":"De Natale","year":"2009","journal-title":"Diabetes Care"},{"key":"2026080920454422700_ehw272C175","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.3945\/ajcn.114.100461","article-title":"A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid\/lipoprotein risk factors for cardiovascular disease in young adults","volume":"101","author":"Stanhope","year":"2015","journal-title":"Am J Clin Nutr"},{"key":"2026080920454422700_ehw272C176","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa020194","article-title":"Effects of the amount and intensity of exercise on plasma lipoproteins","volume":"347","author":"Kraus","year":"2002","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C177","doi-asserted-by":"crossref","first-page":"d636","DOI":"10.1136\/bmj.d636","article-title":"Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: systematic review and meta-analysis of interventional studies","volume":"342","author":"Brien","year":"2011","journal-title":"BMJ"},{"key":"2026080920454422700_ehw272C178","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.numecd.2012.06.002","article-title":"Low glycaemic index diets and blood lipids: a systematic review and meta-analysis of randomised controlled trials","volume":"23","author":"Goff","year":"2013","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2026080920454422700_ehw272C179","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.numecd.2009.08.012","article-title":"Non-soy legume consumption lowers cholesterol levels: a meta-analysis of randomized controlled trials","volume":"21","author":"Bazzano","year":"2011","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2026080920454422700_ehw272C180","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"2026080920454422700_ehw272C181","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jama.2014.10706","article-title":"Long-term follow-up after bariatric surgery: a systematic review","volume":"312","author":"Puzziferri","year":"2014","journal-title":"JAMA"},{"key":"2026080920454422700_ehw272C182","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1161\/CIRCULATIONAHA.108.191627","article-title":"Omega-6 fatty acids and risk for cardiovascular disease: a science advisory from the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention","volume":"119","author":"Harris","year":"2009","journal-title":"Circulation"},{"key":"2026080920454422700_ehw272C183","doi-asserted-by":"crossref","first-page":"515","DOI":"10.7326\/0003-4819-158-7-201304020-00003","article-title":"Plasma phospholipid long-chain omega-3 fatty acids and total and cause-specific mortality in older adults: a cohort study","volume":"158","author":"Mozaffarian","year":"2013","journal-title":"Ann Intern Med"},{"key":"2026080920454422700_ehw272C184","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.atherosclerosis.2008.06.019","article-title":"Nutritional and nutraceutical approaches to dyslipidemia and atherosclerosis prevention: focus on dietary proteins","volume":"203","author":"Sirtori","year":"2009","journal-title":"Atherosclerosis"},{"key":"2026080920454422700_ehw272C185","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.fct.2006.01.017","article-title":"Safety evaluation of phytosterol-esters. Part 9: results of a European post-launch monitoring programme","volume":"44","author":"Lea","year":"2006","journal-title":"Food Chem Toxicol"},{"key":"2026080920454422700_ehw272C186","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/ejcn.2010.178","article-title":"\u03b2-glucan from barley and its lipid-lowering capacity: a meta-analysis of randomized, controlled trials","volume":"64","author":"AbuMweis","year":"2010","journal-title":"Eur J Clin Nutr"},{"key":"2026080920454422700_ehw272C187","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3945\/ajcn.2010.29174","article-title":"Physicochemical properties of oat beta-glucan influence its ability to reduce serum LDL cholesterol in humans: a randomized clinical trial","volume":"92","author":"Wolever","year":"2010","journal-title":"Am J Clin Nutr"},{"key":"2026080920454422700_ehw272C188","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0009-9236(99)70139-6","article-title":"Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors","volume":"65","author":"M\u00e1s","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"2026080920454422700_ehw272C189","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2165\/00044011-200525110-00003","article-title":"Effects of rice policosanol on serum lipoproteins, homocysteine, fibrinogen and C-reactive protein in hypercholesterolaemic patients","volume":"25","author":"Reiner","year":"2005","journal-title":"Clin Drug Investig"},{"key":"2026080920454422700_ehw272C190","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jep.2014.09.049","article-title":"Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension","volume":"161","author":"Lan","year":"2015","journal-title":"J Ethnopharmacol"},{"key":"2026080920454422700_ehw272C191","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2710.2009.01085.x","article-title":"A systematic review and meta-analysis on the therapeutic equivalence of statins","volume":"35","author":"Weng","year":"2010","journal-title":"J Clin Pharm Ther"},{"key":"2026080920454422700_ehw272C192","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/CIRCGENETICS.111.961144","article-title":"Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial","volume":"5","author":"Chasman","year":"2012","journal-title":"Circ Cardiovasc Genet"},{"key":"2026080920454422700_ehw272C193","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.numecd.2014.05.009","article-title":"Resistance and intolerance to statins","volume":"24","author":"Reiner","year":"2014","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2026080920454422700_ehw272C194","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1161\/01.CIR.91.8.2274","article-title":"Cholesterol reduction yields clinical benefit. A new look at old data","volume":"91","author":"Gould","year":"1995","journal-title":"Circulation"},{"key":"2026080920454422700_ehw272C195","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.CIR.97.10.946","article-title":"Cholesterol reduction yields clinical benefit: impact of statin trials","volume":"97","author":"Gould","year":"1998","journal-title":"Circulation"},{"key":"2026080920454422700_ehw272C196","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"2026080920454422700_ehw272C197","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00392-006-0403-x","article-title":"Low density lipoprotein cholesterol, statins and cardiovascular events: a meta-analysis","volume":"95","author":"Genser","year":"2006","journal-title":"Clin Res Cardiol"},{"key":"2026080920454422700_ehw272C198","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/qjmed\/hcq165","article-title":"Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials","volume":"104","author":"Mills","year":"2011","journal-title":"QJM"},{"key":"2026080920454422700_ehw272C199","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1001\/archinternmed.2010.182","article-title":"Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants","volume":"170","author":"Ray","year":"2010","journal-title":"Arch Intern Med"},{"key":"2026080920454422700_ehw272C200","first-page":"CD004816","article-title":"Statins for the primary prevention of cardiovascular disease","volume":"1","author":"Taylor","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"(23 Suppl 1)","key":"2026080920454422700_ehw272C201","first-page":"III-39","article-title":"Beneficial cardiovascular pleiotropic effects of statins","volume":"109","author":"Davignon","year":"2004","journal-title":"Circulation"},{"key":"2026080920454422700_ehw272C202","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1253\/circj.CJ-10-0110","article-title":"Pleiotropic effects of statins. Basic research and clinical perspectives","volume":"74","author":"Zhou","year":"2010","journal-title":"Circulation J"},{"issue":"(Suppl 1)","key":"2026080920454422700_ehw272C203","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2165\/1158822-S0-000000000-00000","article-title":"Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering","volume":"10","author":"Pedersen","year":"2010","journal-title":"Am J Cardiovasc Drugs"},{"key":"2026080920454422700_ehw272C204","first-page":"CD007514","article-title":"Statins for the treatment of dementia","volume":"7","author":"McGuinness","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2026080920454422700_ehw272C205","first-page":"CD008623","article-title":"Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"12","author":"Eslami","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2026080920454422700_ehw272C206","doi-asserted-by":"crossref","first-page":"e29849","DOI":"10.1371\/journal.pone.0029849","article-title":"Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy","volume":"7","author":"Cholesterol Treatment Trialists' (CTT) Collaboration","year":"2012","journal-title":"PLoS One"},{"key":"2026080920454422700_ehw272C207","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1056\/NEJMoa1201735","article-title":"Statin use and reduced cancer-related mortality","volume":"367","author":"Nielsen","year":"2012","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C208","first-page":"CD008203","article-title":"Statins for primary prevention of venous thromboembolism","volume":"12","author":"Li","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"2026080920454422700_ehw272C209","first-page":"CD008565","article-title":"Statins for women with polycystic ovary syndrome not actively trying to conceive","volume":"10","author":"Raval","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"2026080920454422700_ehw272C210","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1177\/1715163515578692","article-title":"Statins and their effect on cognition: let's clear up the confusion","volume":"148","author":"Gauthier","year":"2015","journal-title":"Can Pharm J (Ott)"},{"key":"2026080920454422700_ehw272C211","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"issue":"(8A)","key":"2026080920454422700_ehw272C212","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am J Cardiol"},{"key":"2026080920454422700_ehw272C213","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1177\/2047487314550805","article-title":"What proportion of symptomatic side-effects in patients taking statins are genuinely caused by the drug? A response to letters","volume":"22","author":"Finegold","year":"2015","journal-title":"Eur J Prev Cardiol"},{"key":"2026080920454422700_ehw272C214","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1161\/CIRCOUTCOMES.111.000071","article-title":"Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials","volume":"6","author":"Naci","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026080920454422700_ehw272C215","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2014the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"issue":"(8A)","key":"2026080920454422700_ehw272C216","doi-asserted-by":"crossref","first-page":"32C","DOI":"10.1016\/j.amjcard.2005.12.008","article-title":"Statin safety: an appraisal from the adverse event reporting system","volume":"97","author":"Davidson","year":"2006","journal-title":"Am J Cardiol"},{"key":"2026080920454422700_ehw272C217","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","article-title":"Effect of statins on skeletal muscle function","volume":"127","author":"Parker","year":"2013","journal-title":"Circulation"},{"key":"2026080920454422700_ehw272C218","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jacl.2014.09.007","article-title":"Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial","volume":"8","author":"Moriarty","year":"2014","journal-title":"J Clin Lipidol"},{"key":"2026080920454422700_ehw272C219","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026080920454422700_ehw272C220","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1345\/aph.1R509","article-title":"Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy","volume":"47","author":"Keating","year":"2013","journal-title":"Ann Pharmacother"},{"key":"2026080920454422700_ehw272C221","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.amjopharm.2012.05.002","article-title":"FDA drug safety communications: a narrative review and clinical considerations for older adults","volume":"10","author":"Marcum","year":"2012","journal-title":"Am J Geriatr Pharmacother"},{"key":"2026080920454422700_ehw272C222","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1053\/j.gastro.2004.02.015","article-title":"Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity","volume":"126","author":"Chalasani","year":"2004","journal-title":"Gastroenterology"},{"key":"2026080920454422700_ehw272C223","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00000441-200502000-00002","article-title":"Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes","volume":"329","author":"Vuppalanchi","year":"2005","journal-title":"Am J Med Sci"},{"key":"2026080920454422700_ehw272C224","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","article-title":"Statin use and non-alcoholic steatohepatitis in at risk individuals","volume":"63","author":"Dongiovanni","year":"2015","journal-title":"J Hepatol"},{"key":"2026080920454422700_ehw272C225","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"2026080920454422700_ehw272C226","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"2026080920454422700_ehw272C227","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jacc.2012.09.042","article-title":"Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes","volume":"61","author":"Waters","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026080920454422700_ehw272C228","first-page":"CD005019","article-title":"HMG CoA reductase inhibitors (statins) for kidney transplant recipients","volume":"1","author":"Palmer","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2026080920454422700_ehw272C229","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11883-005-0046-9","article-title":"Statins and proteinuria","volume":"7","author":"Vidt","year":"2005","journal-title":"Curr Atheroscler Rep"},{"key":"2026080920454422700_ehw272C230","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1097\/01.ASN.0000138236.82706.EE","article-title":"Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells","volume":"15","author":"Sidaway","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2026080920454422700_ehw272C231","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1517\/14740338.3.6.547","article-title":"Rosuvastatin safety: lessons from the FDA review and post-approval surveillance","volume":"3","author":"Davidson","year":"2004","journal-title":"Expert Opin Drug Saf"},{"key":"2026080920454422700_ehw272C232","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1056\/NEJMp1106689","article-title":"Weighing the benefits of high-dose simvastatin against the risk of myopathy","volume":"365","author":"Egan","year":"2011","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C233","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s11886-013-0397-8","article-title":"Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy","volume":"15","author":"Wiklund","year":"2013","journal-title":"Curr Cardiol Rep"},{"key":"2026080920454422700_ehw272C234","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.amjcard.2007.07.057","article-title":"Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use","volume":"101","author":"Holoshitz","year":"2008","journal-title":"Am J Cardiol"},{"key":"2026080920454422700_ehw272C235","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1463-1326.2008.00917.x","article-title":"Combination statin-fibrate therapy: safety aspects","volume":"11","author":"Franssen","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"2026080920454422700_ehw272C236","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjcard.2006.11.018","article-title":"Safety considerations with niacin therapy","author":"Guyton","year":"2007","journal-title":"Am J Cardiol"},{"key":"2026080920454422700_ehw272C237","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjcard.2005.12.011","article-title":"Statin safety: an assessment using an administrative claims database","author":"Cziraky","year":"2006","journal-title":"Am J Cardiol"},{"key":"2026080920454422700_ehw272C238","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/dme.12295","article-title":"Colesevelam for type 2 diabetes mellitus: an abridged Cochrane review","volume":"31","author":"Ooi","year":"2014","journal-title":"Diabet Med"},{"key":"2026080920454422700_ehw272C239","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"2026080920454422700_ehw272C240","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/0021-9681(83)90138-8","article-title":"Pre-entry characteristics of participants in the Lipid Research Clinics' Coronary Primary Prevention Trial","volume":"36","year":"1983","journal-title":"J Chronic Dis"},{"key":"2026080920454422700_ehw272C241","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1001\/archinte.1992.00400190041009","article-title":"Results of 6 years of post-trial follow-up. The Lipid Research Clinics Investigators","volume":"152","author":"The Lipid Research Clinics Coronary Primary Prevention Trial","year":"1992","journal-title":"Arch Intern Med"},{"key":"2026080920454422700_ehw272C242","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.diabres.2013.12.033","article-title":"Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin","volume":"104","author":"He","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"2026080920454422700_ehw272C243","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis","volume":"359","author":"Rosseb\u00f8","year":"2008","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C244","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2010.08.012","article-title":"Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease","author":"Sharp Collaborative Group","year":"2010","journal-title":"Am Heart J"},{"key":"2026080920454422700_ehw272C245","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1056\/NEJMoa1405386","article-title":"Inactivating mutations in NPC1L1 and protection from coronary heart disease","volume":"371","author":"Myocardial Infarction Genetics Consortium Investigators","year":"2014","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C246","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jacc.2015.05.065","article-title":"Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial","volume":"66","author":"Tsujita","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026080920454422700_ehw272C247","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"2026080920454422700_ehw272C248","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1146\/annurev-pharmtox-011613-140025","article-title":"Targeting PCSK9 for hypercholesterolemia","volume":"54","author":"Norata","year":"2014","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2026080920454422700_ehw272C249","doi-asserted-by":"crossref","first-page":"600","DOI":"10.7326\/M15-2994","article-title":"Proprotein convertase subtilisin\/kexin type 9 monoclonal antibodies for acute coronary syndrome: a narrative review","volume":"164","author":"Navarese","year":"2016","journal-title":"Ann Intern Med"},{"key":"2026080920454422700_ehw272C250","doi-asserted-by":"crossref","first-page":"752","DOI":"10.7326\/M16-0006","article-title":"Comparative efficacy and safety of everolimus-eluting bioresorbable scaffold versus everolimus-eluting metallic stents: a systematic review and meta-analysis","volume":"164","author":"Zhang","year":"2016","journal-title":"Ann Intern Med"},{"key":"2026080920454422700_ehw272C251","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"AIM-HIGH Investigators","year":"2011","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C252","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"HPS2-THRIVE Collaborative Group","year":"2014","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C253","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.amjcard.2009.07.035","article-title":"Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed Forces Regression Study (AFREGS)","volume":"104","author":"Zhao","year":"2009","journal-title":"Am J Cardiol"},{"key":"2026080920454422700_ehw272C254","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40256-013-0037-0","article-title":"Role of colesevelam in combination lipid-lowering therapy","volume":"13","author":"Jones","year":"2013","journal-title":"Am J Cardiovasc Drugs"},{"key":"2026080920454422700_ehw272C255","doi-asserted-by":"crossref","DOI":"10.3402\/fnr.v52i0.1811","article-title":"Plant sterols\/stanols as cholesterol lowering agents: a meta-analysis of randomized controlled trials","volume-title":"Food Nutr Res","author":"Abumweis","year":"2008"},{"key":"2026080920454422700_ehw272C256","doi-asserted-by":"crossref","first-page":"14C","DOI":"10.1016\/0002-9149(84)90851-8","article-title":"Cholesterol and cardiovascular disease. An overview of Lipid Research Clinics (LRC) epidemiologic studies as background for the LRC Coronary Primary Prevention Trial","volume":"54","author":"Tyroler","year":"1984","journal-title":"Am J Cardiol"},{"key":"2026080920454422700_ehw272C257","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"2026080920454422700_ehw272C258","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/HJR.0b013e3283294b1d","article-title":"EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries","volume":"16","author":"Kotseva","year":"2009","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"2026080920454422700_ehw272C259","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1210\/jc.2011-3213","article-title":"Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline","volume":"97","author":"Berglund","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2026080920454422700_ehw272C260","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","article-title":"Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management","volume":"32","author":"Chapman","year":"2011","journal-title":"Eur Heart J"},{"key":"2026080920454422700_ehw272C261","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"2026080920454422700_ehw272C262","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"ACCORD Study Group","year":"2010","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C263","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.pharmthera.2010.01.008","article-title":"Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk","volume":"126","author":"Chapman","year":"2010","journal-title":"Pharmacol Ther"},{"key":"2026080920454422700_ehw272C264","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.atherosclerosis.2014.09.026","article-title":"Combination therapy in dyslipidemia: where are we now?","volume":"237","author":"Catapano","year":"2014","journal-title":"Atherosclerosis"},{"key":"2026080920454422700_ehw272C265","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C266","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C267","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.CIR.86.3.839","article-title":"Distribution, intercorrelations, and significance for risk classification in 6,700 men and 1,500 women. The Bezafibrate Infarction Prevention (BIP) Study Group, Israel","volume":"86","author":"Lipids and lipoproteins in symptomatic coronary heart disease","year":"1992","journal-title":"Circulation"},{"key":"2026080920454422700_ehw272C268","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g4379","article-title":"Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients","author":"Keene","year":"2014","journal-title":"BMJ"},{"key":"2026080920454422700_ehw272C269","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijcard.2015.04.228","article-title":"Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: a meta-analysis of randomized controlled trials","volume":"191","author":"Ip","year":"2015","journal-title":"Int J Cardiol"},{"key":"2026080920454422700_ehw272C270","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis","volume":"375","author":"Jun","year":"2010","journal-title":"Lancet"},{"key":"2026080920454422700_ehw272C271","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.atherosclerosis.2011.04.020","article-title":"Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis","volume":"217","author":"Lee","year":"2011","journal-title":"Atherosclerosis"},{"key":"2026080920454422700_ehw272C272","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/FJC.0b013e318202709f","article-title":"Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis","volume":"57","author":"Bruckert","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026080920454422700_ehw272C273","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjcard.2006.11.016","article-title":"Safety considerations with fibrate therapy","author":"Davidson","year":"2007","journal-title":"Am J Cardiol"},{"key":"2026080920454422700_ehw272C274","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/j.jacc.2012.07.049","article-title":"Effects of fibrates in kidney disease: a systematic review and meta-analysis","volume":"60","author":"Jun","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026080920454422700_ehw272C275","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1161\/ATVBAHA.108.178228","article-title":"Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate","volume":"29","author":"Taskinen","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026080920454422700_ehw272C276","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1515\/cclm-2012-0078","article-title":"Plasma homocysteine and the risk of venous thromboembolism: insights from the FIELD study","volume":"50","author":"Herrmann","year":"2012","journal-title":"Clin Chem Lab Med"},{"key":"2026080920454422700_ehw272C277","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjcard.2008.02.029","article-title":"Mechanism of action of niacin","author":"Kamanna","year":"2008","journal-title":"Am J Cardiol"},{"key":"2026080920454422700_ehw272C278","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.atherosclerosis.2009.12.023","article-title":"Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis","volume":"210","author":"Bruckert","year":"2010","journal-title":"Atherosclerosis"},{"key":"2026080920454422700_ehw272C279","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjcard.2008.02.039","article-title":"Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk","author":"Brown","year":"2008","journal-title":"Am J Cardiol"},{"key":"2026080920454422700_ehw272C280","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.atherosclerosis.2006.02.012","article-title":"Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review","volume":"189","author":"Balk","year":"2006","journal-title":"Atherosclerosis"},{"key":"2026080920454422700_ehw272C281","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.amjcard.2012.05.031","article-title":"Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)","volume":"110","author":"Ballantyne","year":"2012","journal-title":"Am J Cardiol"},{"key":"2026080920454422700_ehw272C282","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.amjcard.2011.04.015","article-title":"Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial)","volume":"108","author":"Bays","year":"2011","journal-title":"Am J Cardiol"},{"key":"2026080920454422700_ehw272C283","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jacl.2013.10.003","article-title":"Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial","volume":"8","author":"Kastelein","year":"2014","journal-title":"J Clin Lipidol"},{"key":"2026080920454422700_ehw272C284","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s11883-011-0210-3","article-title":"Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis","volume":"13","author":"Wei","year":"2011","journal-title":"Curr Atheroscler Rep"},{"key":"2026080920454422700_ehw272C285","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1161\/CIRCOUTCOMES.112.966168","article-title":"Omega 3 fatty acids and cardiovascular outcomes: systematic review and meta-analysis","volume":"5","author":"Kotwal","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026080920454422700_ehw272C286","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"2026080920454422700_ehw272C287","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1136\/bmj.38755.366331.2F","article-title":"Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review","volume":"332","author":"Hooper","year":"2006","journal-title":"BMJ"},{"key":"2026080920454422700_ehw272C288","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1161\/01.CIR.0000014682.14181.F2","article-title":"Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione","volume":"105","author":"Marchioli","year":"2002","journal-title":"Circulation"},{"key":"2026080920454422700_ehw272C289","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/jnci\/djt174","article-title":"Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial","volume":"105","author":"Brasky","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"2026080920454422700_ehw272C290","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.297.5.499","article-title":"Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis","volume":"297","author":"Nicholls","year":"2007","journal-title":"JAMA"},{"key":"2026080920454422700_ehw272C291","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1194\/jlr.P002816","article-title":"Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database","volume":"51","author":"Barter","year":"2010","journal-title":"J Lipid Res"},{"key":"2026080920454422700_ehw272C292","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJMoa064278","article-title":"HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C293","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3132\/dvdr.2008.046","article-title":"The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient","volume":"5","author":"Fruchart","year":"2008","journal-title":"Diab Vasc Dis Res"},{"key":"2026080920454422700_ehw272C294","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C295","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/ng.2797","article-title":"Discovery and refinement of loci associated with lipid levels","volume":"45","author":"Global Lipids Genetics Consortium","year":"2013","journal-title":"Nat Genet"},{"key":"2026080920454422700_ehw272C296","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1161\/hq0202.104059","article-title":"Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study","volume":"22","author":"Veerkamp","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026080920454422700_ehw272C297","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1210\/jc.2012-1563","article-title":"Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication","volume":"97","author":"Benn","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2026080920454422700_ehw272C298","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1161\/CIRCULATIONAHA.115.018791","article-title":"Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES)","volume":"133","author":"de Ferranti","year":"2016","journal-title":"Circulation"},{"key":"2026080920454422700_ehw272C299","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/bmj.303.6807.893","article-title":"Scientific Steering Committee on behalf of the Simon Broome Register Group","volume":"303","author":"Risk of fatal coronary heart disease in familial hypercholesterolaemia","year":"1991","journal-title":"BMJ"},{"key":"2026080920454422700_ehw272C300","article-title":"Human Genetics Programme. Familial hypercholesterolemia: report of a second WHO consultation. WHO\/HGN\/FH\/Cons\/992","author":"World Health Organization","year":"1999"},{"key":"2026080920454422700_ehw272C301","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1055\/s-2004-822987","article-title":"Advanced method for the identification of patients with inherited hypercholesterolemia","volume":"4","author":"Defesche","year":"2004","journal-title":"Semin Vasc Med"},{"key":"2026080920454422700_ehw272C302","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"key":"2026080920454422700_ehw272C303","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","article-title":"Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment","volume":"36","author":"Wiegman","year":"2015","journal-title":"Eur Heart J"},{"key":"2026080920454422700_ehw272C304","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1161\/ATVBAHA.111.226365","article-title":"An increased burden of common and rare lipid-associated risk alleles contributes to the phenotypic spectrum of hypertriglyceridemia","volume":"31","author":"Johansen","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026080920454422700_ehw272C305","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/gt.2012.43","article-title":"Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial","volume":"20","author":"Gaudet","year":"2013","journal-title":"Gene Ther"},{"key":"2026080920454422700_ehw272C306","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1161\/CIRCRESAHA.113.301464","article-title":"Apolipoprotein C-III: going back to the future for a lipid drug target","volume":"112","author":"Huff","year":"2013","journal-title":"Circ Res"},{"key":"2026080920454422700_ehw272C307","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.pan.2012.05.002","article-title":"A prospective cohort study on risk of acute pancreatitis related to serum triglycerides, cholesterol and fasting glucose","volume":"12","author":"Lindkvist","year":"2012","journal-title":"Pancreatology"},{"key":"2026080920454422700_ehw272C308","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/MOL.0b013e3283319a1d","article-title":"Severe hypertriglyceridemia and pancreatitis: presentation and management","volume":"20","author":"Ewald","year":"2009","journal-title":"Curr Opin Lipidol"},{"key":"2026080920454422700_ehw272C309","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.atherosclerosis.2014.04.003","article-title":"Lysosomal acid lipase deficiency\u2014an under-recognized cause of dyslipidaemia and liver dysfunction","volume":"235","author":"Reiner","year":"2014","journal-title":"Atherosclerosis"},{"issue":"(Suppl 5)","key":"2026080920454422700_ehw272C310","first-page":"S213","article-title":"Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report","volume":"128","author":"National Heart, Lung, and Blood Institute","year":"2011","journal-title":"Pediatrics"},{"key":"2026080920454422700_ehw272C311","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1161\/CIRCRESAHA.113.302952","article-title":"Impact of early evidence of atherosclerotic changes on early treatment in children with familial hypercholesterolemia","volume":"114","author":"Reiner","year":"2014","journal-title":"Circ Res"},{"key":"2026080920454422700_ehw272C312","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00043798-200204000-00001","article-title":"Do lipids, blood pressure, diabetes, and smoking confer equal risk of myocardial infarction in women as in men? The Reykjavik Study","volume":"9","author":"Jonsdottir","year":"2002","journal-title":"J Cardiovasc Risk"},{"key":"2026080920454422700_ehw272C313","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/eurheartj\/ehs411","article-title":"Update on acute coronary syndromes: the pathologists' view","volume":"34","author":"Falk","year":"2013","journal-title":"Eur Heart J"},{"key":"2026080920454422700_ehw272C314","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1001\/jama.291.18.2243","article-title":"Drug treatment of hyperlipidemia in women","volume":"291","author":"Walsh","year":"2004","journal-title":"JAMA"},{"key":"2026080920454422700_ehw272C315","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1007\/s00125-014-3344-3","article-title":"Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study","volume":"57","author":"d'Emden","year":"2014","journal-title":"Diabetologia"},{"key":"2026080920454422700_ehw272C316","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1093\/humrep\/17.9.2307","article-title":"Myocardial infarction and third generation oral contraceptives: aggregation of recent studies","volume":"17","author":"Spitzer","year":"2002","journal-title":"Human Reprod"},{"key":"2026080920454422700_ehw272C317","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jacc.2008.09.042","article-title":"Contraceptive hormone use and cardiovascular disease","volume":"53","author":"Shufelt","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026080920454422700_ehw272C318","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa030808","article-title":"Estrogen plus progestin and the risk of coronary heart disease","volume":"349","author":"Manson","year":"2003","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C319","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/eurheartj\/ehr364","article-title":"Better treatment and improved prognosis in elderly patients with AMI: but do registers tell the whole truth","volume":"33","author":"Rosengren","year":"2012","journal-title":"Eur Heart J"},{"key":"2026080920454422700_ehw272C320","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/eurheartj\/ehr381","article-title":"Resolving inequalities in care? Reduced mortality in the elderly after acute coronary syndromes. The Myocardial Ischaemia National Audit Project 2003\u20132010","volume":"33","author":"Gale","year":"2012","journal-title":"Eur Heart J"},{"key":"2026080920454422700_ehw272C321","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","article-title":"Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths","volume":"370","author":"Prospective Studies Collaboration","year":"2007","journal-title":"Lancet"},{"key":"2026080920454422700_ehw272C322","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1053\/euhj.1998.1243","article-title":"Recommendations of the Second Joint Task Force of European and other societies on coronary prevention","volume":"19","author":"Prevention of coronary heart disease in clinical practice","year":"1998","journal-title":"Eur Heart J"},{"key":"2026080920454422700_ehw272C323","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1012848","article-title":"Lifetime risks of cardiovascular disease","volume":"366","author":"Berry","year":"2012","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C324","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/eurheartj\/ehs458","article-title":"Stroke and coronary heart disease: predictive power of standard risk factors into old age\u2014long-term cumulative risk study among men in Gothenburg, Sweden","volume":"34","author":"Giang","year":"2013","journal-title":"Eur Heart J"},{"key":"2026080920454422700_ehw272C325","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2796.2010.02331.x","article-title":"Factors associated with reaching 90 years of age: a study of men born in 1913 in Gothenburg, Sweden","volume":"269","author":"Wilhelmsen","year":"2011","journal-title":"J Intern Med"},{"key":"2026080920454422700_ehw272C326","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s11883-014-0420-6","article-title":"Primary prevention of cardiovascular disease with statins in the elderly","volume":"16","author":"Reiner","year":"2014","journal-title":"Curr Atheroscler Rep"},{"key":"2026080920454422700_ehw272C327","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/j.jacc.2013.07.069","article-title":"Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis","volume":"62","author":"Savarese","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026080920454422700_ehw272C328","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"2026080920454422700_ehw272C329","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-152-8-201004200-00005","article-title":"Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial","volume":"152","author":"Glynn","year":"2010","journal-title":"Ann Intern Med"},{"key":"2026080920454422700_ehw272C330","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"2026080920454422700_ehw272C331","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1161\/CIRCULATIONAHA.106.654756","article-title":"Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE)","volume":"115","author":"Deedwania","year":"2007","journal-title":"Circulation"},{"key":"2026080920454422700_ehw272C332","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1161\/01.CIR.96.12.4211","article-title":"Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S)","volume":"96","author":"Miettinen","year":"1997","journal-title":"Circulation"},{"key":"2026080920454422700_ehw272C333","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","journal-title":"Lancet"},{"key":"2026080920454422700_ehw272C334","doi-asserted-by":"crossref","first-page":"931","DOI":"10.7326\/0003-4819-134-10-200105150-00007","article-title":"Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial","volume":"134","author":"Hunt","year":"2001","journal-title":"Ann Intern Med"},{"key":"2026080920454422700_ehw272C335","doi-asserted-by":"crossref","first-page":"681","DOI":"10.7326\/0003-4819-129-9-199811010-00002","article-title":"Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial","volume":"129","author":"Lewis","year":"1998","journal-title":"Ann Intern Med"},{"key":"2026080920454422700_ehw272C336","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-147-1-200707030-00002","article-title":"Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease","volume":"147","author":"Wenger","year":"2007","journal-title":"Ann Intern Med"},{"key":"2026080920454422700_ehw272C337","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jacc.2010.01.013","article-title":"Cardiovascular and cancer mortality in very elderly post-myocardial infarction patients receiving statin treatment","volume":"55","author":"Gr\u00e4nsbo","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026080920454422700_ehw272C338","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S2213-8587(13)70112-8","article-title":"Diabetes: a 21st century challenge","volume":"2","author":"Zimmet","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026080920454422700_ehw272C339","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1008862","article-title":"Diabetes mellitus, fasting glucose, and risk of cause-specific death","volume":"364","author":"Emerging Risk Factors Collaboration","year":"2011","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C340","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1056\/NEJMoa1310799","article-title":"Changes in diabetes-related complications in the United States, 1990\u20132010","volume":"370","author":"Gregg","year":"2014","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C341","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Emerging Risk Factors Collaboration","year":"2010","journal-title":"Lancet"},{"key":"2026080920454422700_ehw272C342","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s00125-012-2817-5","article-title":"Revisiting the links between glycaemia, diabetes and cardiovascular disease","volume":"56","author":"Sattar","year":"2013","journal-title":"Diabetologia"},{"key":"2026080920454422700_ehw272C343","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ahj.2007.01.003","article-title":"Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome","volume":"153","author":"Liu","year":"2007","journal-title":"Am Heart J"},{"key":"2026080920454422700_ehw272C344","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1161\/CIRCULATIONAHA.111.067264","article-title":"Body fat distribution and risk of cardiovascular disease: an update","volume":"126","author":"Despres","year":"2012","journal-title":"Circulation"},{"key":"2026080920454422700_ehw272C345","first-page":"765","article-title":"Diabetes and mortality following acute coronary syndromes","volume":"298","author":"Donahoe","journal-title":"JAMA 2007;"},{"key":"2026080920454422700_ehw272C346","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1152\/physrev.00033.2011","article-title":"Pathophysiology of human visceral obesity: an update","volume":"93","author":"Tchernof","year":"2013","journal-title":"Physiol Rev"},{"key":"2026080920454422700_ehw272C347","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1472-6823-14-9","article-title":"The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies","volume":"14","author":"van Vliet-Ostaptchouk","year":"2014","journal-title":"BMC Endocr Disord"},{"key":"2026080920454422700_ehw272C348","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.jacc.2010.05.034","article-title":"The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis","volume":"56","author":"Mottillo","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026080920454422700_ehw272C349","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1161\/ATVBAHA.107.160192","article-title":"Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome","volume":"28","author":"Adiels","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026080920454422700_ehw272C350","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.atherosclerosis.2015.01.039","article-title":"New insights into the pathophysiology of dyslipidemia in type 2 diabetes","volume":"239","author":"Taskinen","year":"2015","journal-title":"Atherosclerosis"},{"key":"2026080920454422700_ehw272C351","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2337\/dc08-1543","article-title":"Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study","volume":"32","author":"Scott","year":"2009","journal-title":"Diabetes Care"},{"key":"2026080920454422700_ehw272C352","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1161\/hc5001.100624","article-title":"Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S","volume":"104","author":"Ballantyne","year":"2001","journal-title":"Circulation"},{"key":"2026080920454422700_ehw272C353","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijcard.2008.11.211","article-title":"Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus\u2014a pooled meta-analysis of randomized placebo-controlled clinical trials","volume":"141","author":"Saha","year":"2010","journal-title":"Int J Cardiol"},{"key":"2026080920454422700_ehw272C354","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2337\/dc07-1117","article-title":"Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study","volume":"31","author":"Ilanne-Parikka","year":"2008","journal-title":"Diabetes Care"},{"key":"2026080920454422700_ehw272C355","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s00125-003-1116-6","article-title":"Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes","volume":"46","author":"Laing","year":"2003","journal-title":"Diabetologia"},{"key":"2026080920454422700_ehw272C356","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.metabol.2013.10.002","article-title":"Type 1 diabetes, metabolic syndrome and cardiovascular risk","volume":"63","author":"Chillaron","year":"2014","journal-title":"Metabolism"},{"key":"2026080920454422700_ehw272C357","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"key":"2026080920454422700_ehw272C358","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA"},{"key":"2026080920454422700_ehw272C359","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"key":"2026080920454422700_ehw272C360","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.jacc.2005.03.077","article-title":"Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial","volume":"46","author":"Ray","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2026080920454422700_ehw272C361","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1001\/2012.jama.11374","article-title":"Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis","volume":"308","author":"Rizos","year":"2012","journal-title":"JAMA"},{"key":"2026080920454422700_ehw272C362","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C363","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jacc.2009.05.028","article-title":"Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial","volume":"54","author":"Di Sciascio","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026080920454422700_ehw272C364","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1161\/CIRCULATIONAHA.110.002451","article-title":"Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies","volume":"123","author":"Patti","year":"2011","journal-title":"Circulation"},{"key":"2026080920454422700_ehw272C365","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1016\/j.jacc.2009.07.005","article-title":"Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction","volume":"54","author":"Briguori","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026080920454422700_ehw272C366","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jcin.2009.11.021","article-title":"Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial","volume":"3","author":"Kim","year":"2010","journal-title":"JACC Cardiovasc Interv"},{"key":"2026080920454422700_ehw272C367","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.amjmed.2014.05.011","article-title":"Statins and contrast-induced acute kidney injury with coronary angiography","volume":"127","author":"Gandhi","year":"2014","journal-title":"Am J Med"},{"key":"2026080920454422700_ehw272C368","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1071-9164(97)90022-1","article-title":"The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease","volume":"3","author":"Kjekshus","year":"1997","journal-title":"J Card Fail"},{"key":"2026080920454422700_ehw272C369","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","author":"Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group","year":"1998","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C370","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C371","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1016\/j.jacc.2006.03.034","article-title":"Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study","volume":"47","author":"Scirica","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2026080920454422700_ehw272C372","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1161\/CIRCULATIONAHA.106.625574","article-title":"Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study","volume":"115","author":"Khush","year":"2007","journal-title":"Circulation"},{"key":"2026080920454422700_ehw272C373","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C374","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"GISSI-HF Investigators","year":"2008","journal-title":"Lancet"},{"key":"2026080920454422700_ehw272C375","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jchf.2013.12.007","article-title":"Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure)","volume":"2","author":"Rogers","year":"2014","journal-title":"JACC Heart Fail"},{"key":"2026080920454422700_ehw272C376","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(08)61239-8","article-title":"Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"GISSI-HF Investigators","year":"2008","journal-title":"Lancet"},{"key":"2026080920454422700_ehw272C377","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1056\/NEJMoa043876","article-title":"A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis","volume":"352","author":"Cowell","year":"2005","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C378","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/CIRCULATIONAHA.109.900027","article-title":"Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial","volume":"121","author":"Chan","year":"2010","journal-title":"Circulation"},{"key":"2026080920454422700_ehw272C379","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.amjcard.2014.01.414","article-title":"Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL)","volume":"113","author":"Arsenault","year":"2014","journal-title":"Am J Cardiol"},{"key":"2026080920454422700_ehw272C380","doi-asserted-by":"crossref","first-page":"e001111","DOI":"10.1161\/JAHA.114.001111","article-title":"Insights into aortic sclerosis and its relationship with coronary artery disease","volume":"3","author":"Milin","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"2026080920454422700_ehw272C381","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1161\/CIRCULATIONAHA.109.891598","article-title":"Effect of hydroxymethylglutaryl coenzyme-a reductase inhibitors on the long-term progression of rheumatic mitral valve disease","volume":"121","author":"Antonini-Canterin","year":"2010","journal-title":"Circulation"},{"key":"2026080920454422700_ehw272C382","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.amjcard.2003.08.066","article-title":"Effect of statins on the progression of bioprosthetic aortic valve degeneration","volume":"92","author":"Antonini-Canterin","year":"2003","journal-title":"Am J Cardiol"},{"key":"2026080920454422700_ehw272C383","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.3899\/jrheum.090011","article-title":"Risk factors for development of coronary artery disease in women with systemic lupus erythematosus","volume":"36","author":"Goldberg","year":"2009","journal-title":"J Rheumatol"},{"key":"2026080920454422700_ehw272C384","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","article-title":"Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study","volume":"74","author":"Ogdie","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2026080920454422700_ehw272C385","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/ard.2009.113696","article-title":"EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis","volume":"69","author":"Peters","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2026080920454422700_ehw272C386","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/ard.2010.142455","article-title":"Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: a population-based cohort study","volume":"70","author":"De Vera","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2026080920454422700_ehw272C387","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000441425","article-title":"Guidelines for classification of acute kidney diseases and disorders","volume":"131","author":"Barry","year":"2015","journal-title":"Nephron"},{"key":"2026080920454422700_ehw272C388","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s11255-013-0407-1","article-title":"The risk of atherosclerosis in patients with chronic kidney disease","volume":"45","author":"Olechnowicz-Tietz","year":"2013","journal-title":"Int Urol Nephrol"},{"key":"2026080920454422700_ehw272C389","doi-asserted-by":"crossref","first-page":"758","DOI":"10.2174\/1570161111311050013","article-title":"Acute coronary syndromes in patients with chronic kidney disease","volume":"11","author":"Franczyk-Sk\u00f3ra","year":"2013","journal-title":"Curr Vasc Pharmacol"},{"key":"2026080920454422700_ehw272C390","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"key":"2026080920454422700_ehw272C391","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Chronic Kidney Disease Prognosis Consortium","year":"2010","journal-title":"Lancet"},{"key":"2026080920454422700_ehw272C392","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.acvd.2015.06.001","article-title":"Impact of renal failure on all-cause mortality and other outcomes in patients treated by percutaneous coronary intervention","volume":"108","author":"Loncar","year":"2015","journal-title":"Arch Cardiovasc Dis"},{"key":"2026080920454422700_ehw272C393","first-page":"CD007784","article-title":"HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis","volume":"5","author":"Palmer","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2026080920454422700_ehw272C394","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.phrs.2013.03.007","article-title":"Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involving 21,295 participants","volume":"72","author":"Barylski","year":"2013","journal-title":"Pharmacol Res"},{"key":"2026080920454422700_ehw272C395","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C396","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C397","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"2026080920454422700_ehw272C398","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.jacc.2012.12.034","article-title":"Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease","volume":"61","author":"Erickson","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026080920454422700_ehw272C399","doi-asserted-by":"crossref","first-page":"182","DOI":"10.7326\/M13-2453","article-title":"Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline","volume":"160","author":"Tonelli","year":"2014","journal-title":"Ann Intern Med"},{"key":"2026080920454422700_ehw272C400","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJM199509073331003","article-title":"Effect of pravastatin on outcomes after cardiac transplantation","volume":"333","author":"Kobashigawa","year":"1995","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C401","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1161\/01.CIR.96.5.1398","article-title":"Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial","volume":"96","author":"Wenke","year":"1997","journal-title":"Circulation"},{"key":"2026080920454422700_ehw272C402","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/01.CIR.0000151805.86933.35","article-title":"Drug therapy in the heart transplant recipient: part IV: drug-drug interactions","volume":"111","author":"Page","year":"2005","journal-title":"Circulation"},{"key":"2026080920454422700_ehw272C403","first-page":"CD005019","article-title":"HMG CoA reductase inhibitors (statins) for kidney transplant recipients","volume":"2","author":"Navaneethan","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"2026080920454422700_ehw272C404","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/TP.0b013e318198d7d0","article-title":"The efficacy and tolerability of ezetimibe in cardiac transplant recipients taking cyclosporin","volume":"87","author":"Shaw","year":"2009","journal-title":"Transplantation"},{"key":"2026080920454422700_ehw272C405","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1093\/eurheartj\/ehr211","article-title":"ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC)","volume":"32","author":"European Stroke Organisation","year":"2011","journal-title":"Eur Heart J"},{"key":"2026080920454422700_ehw272C406","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1001\/archinte.163.18.2157","article-title":"Knowledge and attitudes regarding cardiovascular disease risk and prevention in patients with coronary or peripheral arterial disease","volume":"163","author":"McDermott","year":"2003","journal-title":"Arch Intern Med"},{"key":"2026080920454422700_ehw272C407","first-page":"CD000123","article-title":"Lipid-lowering for peripheral arterial disease of the lower limb","volume":"4","author":"Aung","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"2026080920454422700_ehw272C408","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1093\/eurheartj\/ehu080","article-title":"Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry","volume":"35","author":"Kumbhani","year":"2014","journal-title":"Eur Heart J"},{"key":"2026080920454422700_ehw272C409","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jacc.2013.09.073","article-title":"Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia","volume":"63","author":"Westin","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026080920454422700_ehw272C410","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1161\/01.STR.0000147965.52712.fa","article-title":"Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis","volume":"35","author":"Amarenco","year":"2004","journal-title":"Stroke"},{"key":"2026080920454422700_ehw272C411","doi-asserted-by":"crossref","first-page":"108","DOI":"10.5551\/jat.14001","article-title":"Effect of statin therapy on the progression of common carotid artery intima-media thickness: an updated systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Huang","year":"2013","journal-title":"J Atheroscler Thromb"},{"key":"2026080920454422700_ehw272C412","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.amjcard.2005.05.070","article-title":"Relation of atherosclerotic changes in retinal arteries to the extent of coronary artery disease","volume":"96","author":"Tedeschi-Reiner","year":"2005","journal-title":"Am J Cardiol"},{"key":"2026080920454422700_ehw272C413","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","article-title":"Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial","volume":"370","author":"Keech","year":"2007","journal-title":"Lancet"},{"key":"2026080920454422700_ehw272C414","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1001288","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes","volume":"363","author":"ACCORD Study Group; ACCORD Eye Study Group","year":"2010","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C415","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1161\/01.ATV.0000245819.32762.cb","article-title":"Abdominal aortic aneurysm: pathogenesis and implications for management","volume":"26","author":"Golledge","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026080920454422700_ehw272C416","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ejvs.2006.03.009","article-title":"Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery?","volume":"32","author":"Paraskevas","year":"2006","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2026080920454422700_ehw272C417","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jvs.2004.01.004","article-title":"Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial","volume":"39","author":"Durazzo","year":"2004","journal-title":"J Vasc Surg"},{"key":"2026080920454422700_ehw272C418","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1056\/NEJMoa0808207","article-title":"Fluvastatin and perioperative events in patients undergoing vascular surgery","volume":"361","author":"Schouten","year":"2009","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C419","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ejvs.2012.06.021","article-title":"Effects of statin therapy on abdominal aortic aneurysm growth: a meta-analysis and meta-regression of observational comparative studies","volume":"44","author":"Takagi","year":"2012","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2026080920454422700_ehw272C420","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/eurheartj\/ehq452","article-title":"Statins and renovascular disease in the elderly: a population-based cohort study","volume":"32","author":"Hackam","year":"2011","journal-title":"Eur Heart J"},{"key":"2026080920454422700_ehw272C421","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/2047487313519344","article-title":"Peripheral artery disease is a coronary heart disease risk equivalent among both men and women: results from a nationwide study","volume":"22","author":"Subherwal","year":"2015","journal-title":"Eur J Prev Cardiol"},{"key":"2026080920454422700_ehw272C422","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1474-4422(09)70058-4","article-title":"Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention","volume":"8","author":"Amarenco","year":"2009","journal-title":"Lancet Neurol"},{"key":"2026080920454422700_ehw272C423","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1161\/STROKEAHA.112.655894","article-title":"Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials","volume":"43","author":"McKinney","year":"2012","journal-title":"Stroke"},{"key":"2026080920454422700_ehw272C424","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"2026080920454422700_ehw272C425","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C426","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/01.CIR.103.3.387","article-title":"Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project","volume":"103","author":"Byington","year":"2001","journal-title":"Circulation"},{"key":"2026080920454422700_ehw272C427","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/S0140-6736(11)61125-2","article-title":"Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial","volume":"378","author":"Heart Protection Study Collaborative Group","year":"2011","journal-title":"Lancet"},{"key":"2026080920454422700_ehw272C428","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco","year":"2006","journal-title":"N Engl J Med"},{"key":"2026080920454422700_ehw272C429","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1161\/STROKEAHA.113.001576","article-title":"Reduction in early stroke risk in carotid stenosis with transient ischemic attack associated with statin treatment","volume":"44","author":"Merwick","year":"2013","journal-title":"Stroke"},{"key":"2026080920454422700_ehw272C430","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1001\/jama.289.22.2978","article-title":"Impact of HIV infection and HAART on serum lipids in men","volume":"289","author":"Riddler","year":"2003","journal-title":"JAMA"},{"key":"2026080920454422700_ehw272C431","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/eurheartj\/eht528","article-title":"HIV infection and cardiovascular disease","volume":"35","author":"Hemkens","year":"2014","journal-title":"Eur Heart J"},{"key":"2026080920454422700_ehw272C432","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1468-1293.2012.00996.x","article-title":"Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis","volume":"13","author":"Islam","year":"2012","journal-title":"HIV Med"},{"key":"2026080920454422700_ehw272C433","doi-asserted-by":"crossref","first-page":"e59551","DOI":"10.1371\/journal.pone.0059551","article-title":"Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review","volume":"8","author":"Bavinger","year":"2013","journal-title":"PLoS One"},{"key":"2026080920454422700_ehw272C434","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1210\/jc.2006-2190","article-title":"Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease","volume":"92","author":"Triant","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2026080920454422700_ehw272C435","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1086\/592116","article-title":"Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy","volume":"47","author":"Wohl","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2026080920454422700_ehw272C436","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/00002030-200304110-00010","article-title":"Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART","volume":"17","author":"Calza","year":"2003","journal-title":"AIDS"},{"key":"2026080920454422700_ehw272C437","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/jamapsychiatry.2014.1314","article-title":"Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study","volume":"71","author":"Correll","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"2026080920454422700_ehw272C438","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/bdi.12130","article-title":"Primary prevention of cardiovascular events in patients with major mental illness: a possible role for statins","volume":"15","author":"Andrade","year":"2013","journal-title":"Bipolar Disord"},{"key":"2026080920454422700_ehw272C439","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","article-title":"11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)","volume":"374","author":"Tiihonen","year":"2009","journal-title":"Lancet"},{"key":"2026080920454422700_ehw272C440","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2011.06.008","article-title":"Life expectancy among persons with schizophrenia or bipolar affective disorder","volume":"131","author":"Laursen","year":"2011","journal-title":"Schizophr Res"},{"key":"2026080920454422700_ehw272C441","article-title":"Metabolic syndrome in a French cohort of patients with bipolar disorder: results from the FACE-BD cohort","author":"Godin","year":"1085","journal-title":"J Clin Psychiatry 2014;75:1078\u20131085; quiz"},{"key":"2026080920454422700_ehw272C442","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1177\/070674371005501202","article-title":"The epidemiology of excess mortality in people with mental illness","volume":"55","author":"Lawrence","year":"2010","journal-title":"Can J Psychiatry"},{"key":"2026080920454422700_ehw272C443","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1399-5618.2009.00735.x","article-title":"Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States","volume":"11","author":"Goldstein","year":"2009","journal-title":"Bipolar Disord"},{"key":"2026080920454422700_ehw272C444","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.eurpsy.2009.01.005","article-title":"Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)","volume":"24","author":"De Hert","year":"2009","journal-title":"Eur Psychiatry"},{"key":"2026080920454422700_ehw272C445","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/0269881107077815","article-title":"Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents","volume":"22","author":"Ojala","year":"2008","journal-title":"J Psychopharmacol"},{"issue":"(4 Suppl)","key":"2026080920454422700_ehw272C446","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/1359786810382056","article-title":"Do deficits in cardiac care influence high mortality rates in schizophrenia? A systematic review and pooled analysis","volume":"24","author":"Mitchell","year":"2010","journal-title":"J Psychopharmacol"},{"key":"2026080920454422700_ehw272C447","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/S0140-6736(08)60868-5","article-title":"Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial","volume":"371","author":"Wood","year":"2008","journal-title":"Lancet"},{"key":"2026080920454422700_ehw272C448","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s12160-013-9486-6","article-title":"The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: building an international consensus for the reporting of behavior change interventions","volume":"46","author":"Michie","year":"2013","journal-title":"Ann Behav Med"},{"key":"2026080920454422700_ehw272C449","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ijnurstu.2012.09.010","article-title":"Developing and evaluating complex interventions: the new Medical Research Council guidance","volume":"50","author":"Craig","year":"2013","journal-title":"Int J Nurs Stud"},{"key":"2026080920454422700_ehw272C450","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/jama.288.4.455","article-title":"Long-term persistence in use of statin therapy in elderly patients","volume":"288","author":"Benner","year":"2002","journal-title":"JAMA"},{"key":"2026080920454422700_ehw272C451","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.clinthera.2008.11.012","article-title":"Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel","volume":"30","author":"Chodick","year":"2008","journal-title":"Clin Ther"},{"key":"2026080920454422700_ehw272C452","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jama.288.4.462","article-title":"Adherence with statin therapy in elderly patients with and without acute coronary syndromes","volume":"288","author":"Jackevicius","year":"2002","journal-title":"JAMA"},{"key":"2026080920454422700_ehw272C453","first-page":"689","article-title":"Statin adherence and mortality in patients enrolled in a secondary prevention program","volume":"15","author":"McGinnis","year":"2009","journal-title":"Am J Manag Care"},{"key":"2026080920454422700_ehw272C454","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF02849887","article-title":"Medication adherence trends with statins","volume":"22","author":"Huser","year":"2005","journal-title":"Adv Ther"},{"key":"2026080920454422700_ehw272C455","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ahj.2011.06.007","article-title":"Medication adherence: a call for action","volume":"162","author":"Bosworth","year":"2011","journal-title":"Am Heart J"},{"key":"2026080920454422700_ehw272C456","volume-title":"Patient Adherence to Treatment with Statins for the Prevention of Cardiovascular Disease","author":"Hinchcliffe","year":"2011"},{"key":"2026080920454422700_ehw272C457","first-page":"485","article-title":"Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study","volume":"21","author":"Blackburn","year":"2005","journal-title":"Can J Cardiol"},{"key":"2026080920454422700_ehw272C458","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/heart.88.3.229","article-title":"Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study","volume":"88","author":"Wei","year":"2002","journal-title":"Heart"},{"key":"2026080920454422700_ehw272C459","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.clinthera.2010.02.004","article-title":"Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy","volume":"32","author":"Corrao","year":"2010","journal-title":"Clin Ther"},{"key":"2026080920454422700_ehw272C460","first-page":"459","article-title":"Is there a relationship between early statin compliance and a reduction in healthcare utilization","volume":"16","author":"Aubert","year":"2010","journal-title":"Am J Manag Care"},{"key":"2026080920454422700_ehw272C461","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/01.mlr.0000163641.86870.af","article-title":"Impact of medication adherence on hospitalization risk and healthcare cost","volume":"43","author":"Sokol","year":"2005","journal-title":"Med Care"},{"key":"2026080920454422700_ehw272C462","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.amjmed.2011.12.013","article-title":"Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients","volume":"125","author":"Naderi","year":"2012","journal-title":"Am J Med"},{"key":"2026080920454422700_ehw272C463","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g3937","article-title":"Open letter raises concerns about NICE guidance on statins","volume":"348","author":"Wise","year":"2014","journal-title":"BMJ"},{"key":"2026080920454422700_ehw272C464","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f6123","article-title":"Should people at low risk of cardiovascular disease take a statin?","volume":"347","author":"Abramson","year":"2013","journal-title":"BMJ"},{"key":"2026080920454422700_ehw272C465","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g1520","article-title":"Huffman and colleagues' response to Abramson and colleagues' article on statins in low risk people","volume":"348","author":"Huffman","year":"2014","journal-title":"BMJ"},{"key":"2026080920454422700_ehw272C466","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0749-5978(91)90020-T","article-title":"The Theory of Planned Behaviour","volume":"50","author":"Ajzen","year":"1991","journal-title":"Organ Behav Hum Decis Process"},{"key":"2026080920454422700_ehw272C467","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1177\/109019817400200407","article-title":"The Health Belief Model and personal health behaviour","volume":"2","author":"Becker","year":"1974","journal-title":"Health Educ Monogr"},{"key":"2026080920454422700_ehw272C468","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s10865-015-9644-3","article-title":"Theory of planned behavior and adherence in chronic illness: a meta-analysis","volume":"38","author":"Rich","year":"2015","journal-title":"J Behav Med"},{"key":"2026080920454422700_ehw272C469","doi-asserted-by":"crossref","first-page":"922","DOI":"10.4103\/2141-9248.144914","article-title":"Determinants of patient's adherence to hypertension medications: application of health belief model among rural patients","volume":"4","author":"Kamran","year":"2014","journal-title":"Ann Med Health Sci Res"},{"key":"2026080920454422700_ehw272C470","first-page":"7","article-title":"Applying COM-B to medication adherence","volume":"16","author":"Jackson","year":"2014","journal-title":"Eur Health Psychol"},{"key":"2026080920454422700_ehw272C471","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1748-5908-6-42","article-title":"The behaviour change wheel: a new method for characterising and designing behaviour change interventions","volume":"6","author":"Michie","year":"2011","journal-title":"Implement Sci"},{"key":"2026080920454422700_ehw272C472","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1345\/aph.1P150","article-title":"Predictors of nonadherence to statins: a systematic review and meta-analysis","volume":"44","author":"Mann","year":"2010","journal-title":"Ann Pharmacother"},{"key":"2026080920454422700_ehw272C473","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2261-11-46","article-title":"Adherence with statins in a real-life setting is better when associated cardiovascular risk factors increase: a cohort study","volume":"11","author":"Latry","year":"2011","journal-title":"BMC Cardiovascular Disorders"},{"key":"2026080920454422700_ehw272C474","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ahj.2013.02.011","article-title":"Gender and racial disparities in adherence to statin therapy: a meta-analysis","volume":"165","author":"Lewey","year":"2013","journal-title":"Am Heart J"},{"key":"2026080920454422700_ehw272C475","first-page":"e133","article-title":"Primary nonadherence to statin therapy: patients' perceptions","volume":"19","author":"Harrison","year":"2013","journal-title":"Am J Manag Care"},{"key":"2026080920454422700_ehw272C476","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.outlook.2010.12.002","article-title":"Developing and testing the health literacy universal precautions toolkit","volume":"59","author":"DeWalt","year":"2011","journal-title":"Nurs Outlook"},{"key":"2026080920454422700_ehw272C477","first-page":"305","article-title":"Motivational interviewing: a systematic review and meta-analysis","volume":"55","author":"Rubak","year":"2005","journal-title":"Br J Gen Pract"},{"key":"2026080920454422700_ehw272C478","volume-title":"Self-Efficacy: The Exercise of Control","author":"Bandura","year":"1997"},{"key":"2026080920454422700_ehw272C479","first-page":"CD004371","article-title":"Interventions to improve adherence to lipid lowering medication","volume":"3","author":"Schedlbauer","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"2026080920454422700_ehw272C480","first-page":"CD000011","article-title":"Interventions for enhancing medication adherence","volume":"11","author":"Nieuwlaat","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2026080920454422700_ehw272C481","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jacc.2015.01.043","article-title":"Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC\/AHA Guidelines","volume":"65","author":"Martin","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026080920454422700_ehw272C482","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2013.277064","article-title":"Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial","volume":"310","author":"Thom","year":"2013","journal-title":"JAMA"},{"key":"2026080920454422700_ehw272C483","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/j.jacc.2014.08.021","article-title":"A polypill strategy to improve adherence: results from the FOCUS project","volume":"64","author":"Castellano","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026080920454422700_ehw272C484","first-page":"CD007768","article-title":"Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews","volume":"4","author":"Ryan","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2026080920454422700_ehw272C485","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/37\/39\/2999\/70580230\/eurheartj_37_39_2999.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/37\/39\/2999\/70580230\/eurheartj_37_39_2999.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:46:46Z","timestamp":1786322806000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/37\/39\/2999\/2414995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,28]]},"references-count":485,"journal-issue":{"issue":"39","published-online":{"date-parts":[[2016,8,28]]},"published-print":{"date-parts":[[2016,10,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehw272","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,10,14]]},"published":{"date-parts":[[2016,8,28]]}}}